Granahan Investment Management LLC Has $6.26 Million Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Granahan Investment Management LLC decreased its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 12.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 567,689 shares of the company's stock after selling 77,281 shares during the period. Granahan Investment Management LLC owned approximately 1.07% of Stoke Therapeutics worth $6,262,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in STOK. Norges Bank acquired a new stake in shares of Stoke Therapeutics during the 4th quarter valued at approximately $3,472,000. Schonfeld Strategic Advisors LLC acquired a new position in Stoke Therapeutics during the fourth quarter worth $3,218,000. Dimensional Fund Advisors LP grew its holdings in Stoke Therapeutics by 103.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 538,900 shares of the company's stock valued at $5,943,000 after purchasing an additional 273,890 shares during the last quarter. Baker BROS. Advisors LP increased its position in shares of Stoke Therapeutics by 6.1% in the fourth quarter. Baker BROS. Advisors LP now owns 4,633,838 shares of the company's stock valued at $51,111,000 after buying an additional 265,395 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of Stoke Therapeutics during the 4th quarter worth $1,423,000.

Stoke Therapeutics Stock Up 6.0%

STOK stock traded up $0.54 during trading hours on Thursday, hitting $9.53. The company's stock had a trading volume of 315,456 shares, compared to its average volume of 714,972. The company has a market capitalization of $520.31 million, a PE ratio of -4.53 and a beta of 1.20. The stock has a 50 day moving average price of $8.09 and a two-hundred day moving average price of $10.01. Stoke Therapeutics, Inc. has a 12 month low of $5.35 and a 12 month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The business had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million. Sell-side analysts expect that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on STOK. Cantor Fitzgerald raised Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday. Needham & Company LLC restated a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, April 9th. Chardan Capital reiterated a "buy" rating and issued a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Finally, HC Wainwright lowered their price objective on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a research note on Wednesday. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Stoke Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $23.20.

Insider Buying and Selling

In other news, insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the sale, the insider now owns 63,962 shares in the company, valued at $554,550.54. The trade was a 5.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Edward M. Md Kaye sold 10,382 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the transaction, the director now owns 148,253 shares of the company's stock, valued at approximately $1,285,353.51. This represents a 6.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 16,532 shares of company stock worth $143,332 in the last three months. Insiders own 11.30% of the company's stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.